| __timestamp | BioMarin Pharmaceutical Inc. | Cytokinetics, Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 17268000 |
| Thursday, January 1, 2015 | 402271000 | 19667000 |
| Friday, January 1, 2016 | 476593000 | 27823000 |
| Sunday, January 1, 2017 | 554336000 | 36468000 |
| Monday, January 1, 2018 | 604353000 | 31282000 |
| Tuesday, January 1, 2019 | 680924000 | 39610000 |
| Wednesday, January 1, 2020 | 737669000 | 52820000 |
| Friday, January 1, 2021 | 759375000 | 96803000 |
| Saturday, January 1, 2022 | 854009000 | 177977000 |
| Sunday, January 1, 2023 | 937300000 | 173612000 |
| Monday, January 1, 2024 | 1009025000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, BioMarin Pharmaceutical Inc. and Cytokinetics, Incorporated have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. BioMarin's SG&A expenses have surged by over 200% from 2014 to 2023, reflecting its aggressive expansion and market penetration strategies. In contrast, Cytokinetics has experienced a more modest increase of approximately 900% during the same period, indicating a steady yet cautious approach to growth.
BioMarin's expenses peaked in 2023, reaching nearly 9.4 times its 2014 levels, while Cytokinetics saw its highest expenses in 2022, with a slight dip in 2023. These trends highlight the differing strategic priorities of these companies, with BioMarin focusing on rapid expansion and Cytokinetics on sustainable growth. Investors and industry analysts should consider these patterns when evaluating the future potential of these biotech giants.
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Cytokinetics, Incorporated
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: Insmed Incorporated vs BioMarin Pharmaceutical Inc. Trends and Insights
Dr. Reddy's Laboratories Limited and Cytokinetics, Incorporated: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Ascendis Pharma A/S
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Vericel Corporation Trends and Insights
BioMarin Pharmaceutical Inc. and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Xencor, Inc. Trends and Insights
Corcept Therapeutics Incorporated and Cytokinetics, Incorporated: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Amneal Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Cytokinetics, Incorporated or ACADIA Pharmaceuticals Inc.